Pulling SEC filings + quote and writing the call…
Pulling SEC filings + quote and writing the call…
ProMIS Neurosciences Inc.
Last earnings -1.8% on 2026-05-12
High return on equity (3155.8%).
Rules-based read computed from SEC figures — no Anthropic key set. Add ANTHROPIC_API_KEY to .env.local for a full Claude analysis.
ProMIS Neurosciences Inc. shows limited reported revenue, and 3155.8% ROE.
The risks, catalysts, 12-month price target and the cited SEC figures behind this rating — with Pro.
Unlock with Pro€15/mo · cancel anytime
Sources: SEC EDGAR (CIK 0001374339, latest 10-Q filed 2026-05-12) · EODHD · rules-based read · as of 6/18/2026, 1:07:57 PM.
Research and education only — not financial advice. Calls are generated from SEC filings and a delayed/third-party price feed, may be wrong or out of date, and are not a recommendation to buy or sell any security. Do your own research.
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$8.29M | -$23.4M | -$14.3M | -$16.8M | -$40.2M |
| Net income | -$9.79M | -$18.1M | -$13.2M | $2.78M | -$39.7M |
| Diluted EPS | -$1.69 | -$2.41 | -$1.07 | $2.63 | -$22.61 |
| Net margin | — | — | — | — | — |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
501 tracked peers · median